2012 Exam Flashcards
A typical compensatory cardiovascular reflex following treatment of a hypertensive patient with a vasodilator could involve:
A. a reduction in heart rate, an increase in plasma renin levels and an increase in sympathetic nervous system activity.
B. an increase in heart rate, an increase in the force of cardiac contraction, and an increase in soduium and water retention.
C. reduced urine output, reduced cardiac output, and reduced heart rate.
D. increased urinary output, reduced cardiac output and increased heart rate.
B. an increase in heart rate, an increase in the force of cardiac contraction, and an increase in soduium and water retention.
Antihypertensive drugs lower blood pressure by reducing either total peripheral resistance and/or:
A. cardiac output
B. heart rate and/or cardiac stroke volume
C. both A and B
D. neither A nor B
C. both A and B
Which of the following antihypertensive drug classes directly bind to and block L-type calcium channels?
A. Dihydropyridines
B. Minoxidil
C. Nitrovasodilators
D. All of the above
A. Dihydropyridines
Alpha-2 adrenergic receptor agonists as antihypertensive drugs
A. include clonidine (Catapress)
B. reduce sympathetic outflow from the brain
C. are used currently in patients whose hypertension is not well-controlled by other drugs
D. have all of the above properties
D. have all of the above properties
Which of the following best explains the antihypertensive mechanism of action for lisinopril (Prinivil)?
A. Directly blocks AT1 adrenergic receptors
B. Increases angiotensin II levels
C. Reduces renin activity
D. Reduces angiotensin II levels
D. Reduces angiotensin II levels
Which of the following statemwents accurately describes the treatment approach for patients with high blood pressure?
A. Blood pressure normalization might be achieved with life-style modifications (eg. diet and exercise) alone.
B. Use thiazide diuretics for patients with stage I hypertension who have no other compelling indications.
C. Use of a two drug combination for patients with stage II hypertension who have no other compelling indication
D. All of the statements above are true
D. All of the statements above are true
When used for the treatment of angina, nitroglycerin e(Nitrostat)
A. reduces myocardial work by decreasing preload.
B. has low bioavailability when dissolved in the mouth
C. directly reduces cardiac rate and contractility
D. possesses all of the above properties.
A. reduces myocardial work by decreasing preload.
The signs and symptoms of angina pectoris are
A. due to an imbalance between cardiac oxygen demand and oxygen supply
B. frequently attributed to atherosclerotic lesions in coronary arteries.
C. treated with drugs that reduce total peripheral resistance and/or venous return to the heart.
D. attributed partly to pain fibers stimulated by metabolites released from cells within ischemic tissue.
E. consistent with all of the above
D. attributed partly to pain fibers stimulated by metabolites released from cells within ischemic tissue.
Dihydropyridine-type calcium channel blocking drugs, e.g. nifedipine (Procardia), are useful anti-antinal agents because they can
A. lower peripheral vascular resistance.
B. inhibit coronary artery spasm
C. do both A and B.
D. do neither A nor B.
C. do both A and B.
Digitalis glycosides
A. have a large therapeutic index value.
B. increase the intracellular free Ca2+ concentration in cardiac myocytes.
C. are characterized by both A and B.
D. are characterized by neither A nor B.
B. increase the intracellular free Ca2+ concentration in cardiac myocytes.
Which of the following mechanisms contribute to reduced mortality in the pharmacologic treatment of heart failure?
A. Interference with the actions of angiotensin II
B. Partial blockage of cardiac beta-1 adrenergic receptors
C. Blockade of aldosterone receptors
D. All of the above
D. All of the above
The so-called “vicious cycle of heart failure” involves all of the following EXCEPT
A. retention of sodium and water.
B. the development of myocardial hypertrophy.
C. peripheral vasodilation.
D. a reduction in cardiac output.
C. peripheral vasodilation.
Warfarin (Coumadin)
A. inhibits Vitamin K-dependent synthesis of clotting factors
B. is an oral anticoagulant.
C. is contraindicated in pregnancy.
D. is characterized by all the above properties.
D. is characterized by all the above properties.
Alteplase (Activase)
A. selectively prevents platelet aggregation.
B. is a tissue plasminogen activator.
C. inhibits synthesis of thrombin.
D. is characterized by none of the above properties.
B. is a tissue plasminogen activator.
Aspirin
A. prevents binding of fibrinogen to glycoprotein IIb/IIa receptors on platelets.
B. activates ADP receptors on platelets.
C. irreversibly inhibits cyclo-oxygenase (COX).
D. does all of the above.
C. irreversibly inhibits cyclo-oxygenase (COX).
Which one of the following drugs selectively inhibits factor Xa?
A. Streptokinase (Streptase)
B. Dabigatran (Pradaxa)
C. Low molecular weight heparin
D. Clopidogrel (Plavix)
C. Low molecular weight heparin
A new drug is being tested against the standard therapy used to treat advanced lung cancer. Results of the clinical trial show reduced disease progression, indicating potential clinical benefit of the new drug. Investigators are considering filling a new drug application (NDA). In which phase of clinical trials is this new drug?
A. Phase O
B. Phase I
C. Phase II
D. Phase III
D. Phase III
A drug that has a high potential for abuse, and an approved medical use in the US, and for which no automatic refills can be prescribed is placed in which class of controlled substance?
A. Schedule I
B. Schedule II
C. Schedule III
D. Schedule V
B. Schedule II
You have been working for 10 years developing a new drug for potential clinical use. You have collected preclinical data, which you now intend to submit to the FDA to receive investigational new drug (IND) status. Which of the following must be submitted to receive IND status?
A. Chemical synthesis protocols for making the drug
B. Informed consent form for studies performed in humans
C. Toxicology studies performed in animals
D. All of the above
D. All of the above
Phase I clinical trials serve to
A. determine the efficacy of the experimental drug.
B. increase the market of an already approved drug.
C. establish the maximum tolerated dose.
D. priority rank multiple promising compounds.
C. establish the maximum tolerated dose.